8 results on '"Mori, Motomi"'
Search Results
2. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer.
- Author
-
Schwartzman, Jacob, Mongoue-Tchokote, Solange, Gibbs, Angela, Gao, Lina, Corless, Christopher L., Jin, Jennifer, Zarour, Luai, Higano, Celestia, True, Lawrence D., Vessella, Robert L., Wilmot, Beth, Bottomly, Daniel, McWeeney, Shannon K., Bova, G. Steven, Partin, Alan W., Mori, Motomi, and Alumkal, Joshi J.
- Published
- 2011
- Full Text
- View/download PDF
3. C-reactive Protein as a Prognostic Marker for Men With Androgen-independent Prostate Cancer: Results From the ASCENT Trial.
- Author
-
Beer, Tomasz M., Lalani, Alshad S., Lee, Stella, Mori, Motomi, Eilers, Kristine M., Curd, John G., Henner, W. David, Ryan, Christopher W., Venner, Peter, Ruether, J. Dean, and Chi, Kim N.
- Subjects
C-reactive protein ,BIOMARKERS ,PROSTATE cancer prognosis ,CANCER prognosis ,DOCETAXEL ,CANCER research - Abstract
The article presents a study which evaluates the significance of C-reactive protein (CRP) as a prognostic marker for men with androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy. Results of the analyses show that elevated plasma CRP concentrations appear to be a strong predictor of poor survival and lower probability of PSA response to treatment in patients with AIPC who are receiving docetaxel-based therapy.
- Published
- 2008
- Full Text
- View/download PDF
4. Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study.
- Author
-
Graff, Julie N., Mori, Motomi, Li, Hong, Garzotto, Mark, Penson, David, Potosky, Arnold L., and Beer, Tomasz M.
- Subjects
CANCER treatment ,PROSTATE cancer ,CANCER patients ,MALE reproductive organs - Abstract
Purpose: Primary androgen suppression therapy for clinically localized prostate cancer is increasingly common in the United States despite a lack of supportive evidence for its use. We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study. Materials and Methods: In 1994 to 1995 the Prostate Cancer Outcomes Study recruited 3,533 men diagnosed with prostate cancer. Clinical and treatment information was abstracted from medical records and demographic characteristics were obtained from patient surveys 6, 12, 24 and 60 months after diagnosis. Overall and cancer specific mortality was analyzed through December 2002 using the Kaplan-Meier method and Cox regression. Results: A total of 276 patients had organ confined (cT1-2) prostatic adenocarcinoma and received primary androgen suppression therapy within 1 year of diagnosis. Median followup for censored patients was 7.6 years (range 1.1 to 8.1). Five-year overall and cancer specific survival was 66% (95% CI 59–72) and 91% (95% CI 86–94), respectively. Independent predictors of shorter overall survival were patient age 75 years or older, prostate specific antigen 20 ng/ml or greater, Gleason score 7 or greater and abnormal digital rectal examination. Gleason score 7 or greater, prostate specific antigen 20 ng/ml or greater and a low comorbidity index were independent predictors of shorter cancer specific survival. Conclusions: The use of primary androgen suppression therapy in the Prostate Cancer Outcomes Study data set resulted in 91% 5-year cancer specific survival. Advanced age, and factors that reflect tumor burden and biology were predictive of overall survival, while cancer specific survival was predicted by tumor factors and the burden of comorbid conditions. A nomogram for predicting overall survival at 5 years was constructed. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
5. Classification and Regression Tree Analysis for the Prediction of Aggressive Prostate Cancer on Biopsy.
- Author
-
Spurgeon, Stephen E.F., Hsieh, Yi-Ching, Rivadinera, Adrianna, Beer, Tomasz M., Mori, Motomi, and Garzotto, Mark
- Subjects
CANCER patients ,PROSTATE cancer ,MALE reproductive organs ,CLINICAL pathology - Abstract
Purpose: Prostate cancer screening allows early cancer detection but not all patients benefit from subsequent therapy. Thus, identifying patients who are likely to harbor aggressive cancer could significantly decrease the number of prostate biopsies performed. Materials and Methods: Data were collected on 1,563 consecutive referred men with serum PSA 10 ng/ml or less who underwent an initial prostate biopsy. Predictors of aggressive cancer (Gleason sum 7 or greater) were identified using CART analysis. Model building was done in a randomly selected training set (70% of the data) and validation was completed using the remaining data. Results: Cancer was detected in 406 men (26.1%). Gleason 7 or greater cancer was found in 130 men (8.3%). CART created a decision tree that identified certain groups at risk for aggressive cancer, namely 1) PSAD greater than 0.165 ng/ml/cc, and 2) PSAD greater than 0.058 to 0.165 ng/ml/cc or less, age greater than 57.5 years and prostate volume greater than 22.7 cc. The incidence of aggressive prostate cancer was 1.1% when PSAD was 0.058 ng/ml/cc or less in the validation set. The sensitivity and specificity of CART for identifying men with aggressive cancer were 100% and 31.8% for model building data, and 91.5% and 33.5% for the validation data set, respectively. Conclusions: CART identified groups at risk for aggressive prostate cancer. Application of this CART could decrease unnecessary biopsies by 33.5% when only a diagnosis of high grade prostate cancer would lead to subsequent therapy. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
6. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
- Author
-
Janoff, Daniel M., Peterson, Chad, Mongoue-Tchokote, Solange, Peters, Laura, Beer, Tomasz M., Wersinger, Emily M., Mori, Motomi, and Garzotto, Mark
- Subjects
PROSTATE cancer ,MALE reproductive organ diseases ,DISEASES in men ,ANDROGENS ,SEX hormones ,HORMONE therapy - Abstract
Most papers in this section are written about various aspects of prostate cancer, and cover a wide cross-section of subjects relating to this important topic. Interestingly there has been increasing interest by clinical oncologists in this area, and I am delighted to publish their views in this Journal. We as urologists now routinely have multidisciplinary team meetings, and find the insightful comments of the non-urologists very helpful in the management not only of patients with prostate cancer, but also of all types of urological malignancy. To characterize the clinical outcomes of androgen deprivation therapy (ADT) as the sole therapy for localized prostate cancer, and to determine independent predictors of disease progression, as recent studies indicate an increasing use of ADT. The records of all patients with cT1–4NXM0 adenocarcinoma of the prostate treated with ADT as the primary initial therapy at the Portland Veterans Affairs Medical Center between 1993 and 2000 were reviewed. Age, race, Charlson Health Index, family history, prostate-specific antigen (PSA) level, PSA density, digital rectal examination (DRE) findings, Gleason score, and percentage of positive biopsy cores at diagnosis were recorded for 81 patients. Patients had a median ( sd, range) age of 73 (5.6, 58–84) years, a PSA level of 14.3 (34.6, 1.4–252) ng/mL and tumours were classified as Gleason score ≤ 5 in 9% of patients, 6 in 31%, 7 in 31% and 8–10 in 30%. Outcomes extracted were PSA progression, PSA nadir, bone fractures, local progression, distant progression and overall survival. With a median (range) follow-up of 54 (6–115) months, the incidence of local progression, distant progression, bone fractures, PSA progression, and death were 10%, 7%, 25%, 21% and 41% respectively. The percentage of positive biopsy cores ≥ 83%, age < 70 years, Gleason score ≥ 7, abnormal DRE, and PSA nadir ≥ 0.2 ng/mL were significantly associated with PSA progression by univariate analysis. The multivariate analysis identified age < 70 years (hazard ratio 6.52, 95% confidence interval 2.29–18.55) and Gleason score ≥ 6 (4.0, 2.0–12.0) as independent risk factors for PSA progression. ADT resulted in modest control of localized prostate cancer, but younger patients and those with Gleason ≥ 6 cancers were at higher risk of treatment failure. Toxicity, principally in the form of bone fractures, was high. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Predictors of Delayed Therapy after Expectant Management for Localized Prostate Cancer in the Era of Prostate-Specific Antigen.
- Author
-
Panagiotou, Irene, Beer, Tomasz M., Yi-Ching Hsieh, Mori, Motomi, Peters, Laura, Klein, Thomas, and Garzotto, Mark
- Subjects
PROSTATE cancer ,CANCER treatment ,DISEASE management ,ANTIGENS ,ANDROGENS - Abstract
Objective: To identify risk factors for delayed cancer-directed intervention in modern era prostate cancer patients who initially elect expectant management. Materials and Methods: An observational, cohort study of expectantly managed patients, diagnosed with clinical T
1–4 Nx M0 prostate cancer between 1993 and 2000 was carried out. Data including TNM stage, age, serum prostate-specific antigen (PSA), prostate gland volume by transrectal ultrasound, Gleason score, percent biopsies positive for cancer, imaging results, initial treatment selection, and outcome data were collected on all patients. Results: 192 of 561 patients (34.3%) elected expectant management, and follow-up data were available for 187 (97.4%) patients. With a median follow-up of 3.6 years, 90 (48.1%) patients had a cancer-directed intervention. Gleason score (p = 0.0097) and percent of positive biopsy cores (p = 0.03) were independent predictors of time to intervention. As expected, PSA doubling time became the most significant predictor of intervention (p = 0.0057) when added to the model. These independent covariates are able to characterize low-, intermediate- and high-risk groups for cancer-directed intervention. Conclusions: Cancer-directed intervention is common in patients who choose expectant management in the PSA era. Gleason score and percent of positive biopsy cores predict cancer-directed interventions, thus, these patients may be least suitable for expectant management. Copyright © 2004 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
8. Assessment of Prostate-Specific Antigen Doubling Time in Prediction of Prostate Cancer on Needle Biopsy
- Author
-
Spurgeon, Stephen E.F., Mongoue-Tchokote, Solange, Collins, Lauren, Priest, Ryan, Hsieh, Yi-Ching, Peters, Laura M., Beer, Tomasz M., Mori, Motomi, and Garzotto, Mark
- Subjects
- *
PROSTATE cancer , *MALE reproductive organs , *TUMOR antigens , *CLINICAL pathology - Abstract
Objectives: Prostate-specific antigen (PSA) kinetics have failed to predict for the presence of prostate cancer in screening populations in which many patients harbor subclinical disease. We hypothesized that the prebiopsy PSA doubling time (PSADT) and PSA velocity (PSAV) could predict for cancer detection in a referral population with a suspicion of prostate cancer.Methods: Data were collected from 1699 consecutive veterans with a PSA level of 10 ng/mL or less who underwent prostate biopsy. Logistic regression analysis was performed on the following: age, race, family history, digital rectal examination findings, PSA, PSA density, PSADT, PSAV, prostate volume, and ultrasound lesions. Model building was accomplished with 70% of the data, and validation was done using the remaining 30%. These data were also analyzed using classification and regression tree analysis.Results: Using logistic regression analysis (P <0.05) on the model building set, prostate cancer was associated with age (older than 70 years), PSA level (greater than 2.9 ng/mL), PSA density (more than 0.12 ng/mL/cm3), digital rectal examination findings, and the presence of a lesion on ultrasonography. A PSADT of 2 to 5 years was marginally associated with prostate cancer detection (odds ratio 1.6, 95% confidence interval 1.1 to 2.3), and a PSADT of less than 2 years or longer than 5 years and PSAV were not predictive. On classification and regression tree analysis, PSADT was not selected as a predictive factor. Furthermore, neither PSADT nor PSAV was predictive of Gleason score 7 or worse cancer.Conclusions: In contrast to its prognostic value after the diagnosis of prostate cancer has been established, PSA kinetics offer little to clinical decision making as predictors of cancer or high-grade cancer in men with a PSA level of 10 ng/mL or less. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.